akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
![Akero Therapeutics logo](/files/LOGO/1744659-AKRO.png)
Company profile
Ticker
AKRO
Exchange
Website
CEO
Andrew Cheng
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Akero Securities Corporation ...
AKRO stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
12 Jun 24
S-3ASR
Automatic shelf registration
10 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
10 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
8-K
Unregistered Sales of Equity Securities
18 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
424B5
Prospectus supplement for primary offering
6 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 623.85 mm | 623.85 mm | 623.85 mm | 623.85 mm | 623.85 mm | 623.85 mm |
Cash burn (monthly) | (no burn) | (no burn) | 19.98 mm | 17.01 mm | 11.71 mm | 12.99 mm |
Cash used (since last report) | n/a | n/a | 55.78 mm | 47.46 mm | 32.69 mm | 36.25 mm |
Cash remaining | n/a | n/a | 568.08 mm | 576.39 mm | 591.16 mm | 587.60 mm |
Runway (months of cash) | n/a | n/a | 28.4 | 33.9 | 50.5 | 45.2 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 77 |
Closed positions | 16 |
Increased positions | 48 |
Reduced positions | 28 |
13F shares | Current |
---|---|
Total value | 1.60 tn |
Total shares | 81.52 mm |
Total puts | 561.40 k |
Total calls | 428.90 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
JHG Janus Henderson | 6.12 mm | $154.59 bn |
RTW Investments | 5.43 mm | $137.21 bn |
General Atlantic | 5.23 mm | $132.21 bn |
Wellington Management | 5.21 mm | $131.69 bn |
BLK Blackrock | 4.89 mm | $123.59 bn |
T. Rowe Price | 4.06 mm | $102.57 mm |
STT State Street | 3.80 mm | $95.93 bn |
Alkeon Capital Management | 3.76 mm | $0.00 |
Vanguard | 3.67 mm | $92.70 bn |
venBio Global Strategic Fund | 3.03 mm | $106.05 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jun 24 | Cheng Andrew | Common Stock | Sell | Dispose S | No | No | 22.641 | 7,894 | 178.73 k | 581,553 |
11 Jun 24 | Patrick Lamy | Common Stock | Sell | Dispose S | No | No | 22.641 | 569 | 12.88 k | 18,562 |
11 Jun 24 | Rolph Timothy | Common Stock | Sell | Dispose S | No | No | 22.641 | 2,380 | 53.89 k | 180,178 |
11 Jun 24 | William Richard White | Common Stock | Sell | Dispose S | No | No | 22.64 | 2,831 | 64.09 k | 46,799 |
11 Jun 24 | Catriona Yale | Common Stock | Sell | Dispose S | No | No | 22.641 | 2,825 | 63.96 k | 74,867 |
News
Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics
20 Jun 24
Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics
12 Jun 24
Wolfe Research Initiates Coverage On Akero Therapeutics with Outperform Rating
11 Jun 24
Akero Therapeutics Begins Phase 3 Study on Efruxifermin for Liver Disease Treatment
11 Jun 24
HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
11 Jun 24
Press releases
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
20 Jun 24
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
20 Jun 24
TUESDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO
20 Jun 24
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
19 Jun 24
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
19 Jun 24